Latest News

Noxopharm to expedite Veyonda Clinical Program
FNN interview with Nox Chief Medical Officer on Interim Data
Chief Medical Officer Discusses DARRT-1 trial interim results
Veyonda and Radiotherapy Delivers Clinical Benefits
Appendix 4C - quarterly report for the quarter ended December 31, 2018
Principal Investigator Discusses LuPIN-1 Study
DARRT-1 study advancing on basis of positive clinical data
NOX announces Positive Data from CEP-1 Study of Veyonda
NOX 2018 AGM Presentations
NOX to Present Clinical Data at COSA Annual Meeting